Targeted Versus Universal Antifungal Prophylaxis Among Liver Transplant Recipients
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Guidelines recommend targeted antifungal prophylaxis for liver transplant (LT) recipients based on tiers of risk, rather than universal prophylaxis. The feasibility and efficacy of tiered, targeted prophylaxis is not well established. We performed a retrospective study of LT recipients who received targeted prophylaxis (n = 145; voriconazole [VORI; 54%], fluconazole [8%], no antifungal [38%]) versus universal VORI prophylaxis (n = 237). Median durations of targeted and universal prophylaxis were 11 and 6 days, respectively (p < 0.0001). The incidence of invasive fungal infections (IFIs) in targeted and universal groups was 6.9% and 4.2% (p = 0.34). Overall, intra-abdominal candidiasis (73%) was the most common IFI. Posttransplant bile leaks (p = 0.001) and living donor transplants (p = 0.04) were independent risk factors for IFI. IFIs occurred in 6% of high-risk transplants who received prophylaxis and 4% of low-risk transplants who did not receive prophylaxis (p = 1.0). Mortality rates (100 days) were 10% (targeted) and 7% (universal) (p = 0.26); attributable mortality due to IFI was 10%. Compliance with prophylaxis recommendations was 97%. Prophylaxis was discontinued for toxicity in 2% of patients. Targeted antifungal prophylaxis in LT recipients was feasible and safe, effectively prevented IFIs and reduced the number of patients exposed to antifungals. Bile leaks and living donor transplants should be considered high-risk indications for prophylaxis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917 · cited 1×
“IFIs were defined according to EORTC/MSG criteria (14); superficial fungal”
MethodPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“On November 1, 2010, we revised our approach from universal VORI prophylaxis to a targeted algorithm that was adapted from AST/IDSA guidelines (Figure 1) (9,12,13).”
MethodMorrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171 · cited 1×
“Most importantly, the low attributable mortality in our study and others (Table S2) suggests that prophylaxis attenuates the severity of IFIs that do develop (21,22).”
BackgroundInvasive Saccharomyces Infection: A Comprehensive Review
Enache-Angoulvant, A., & Hennequin, C. (2005) · Clinical Infectious Diseases · doi:10.1086/497832 · Cited by 369 · cited 1×
“cerevisiae has been reported to cause invasive infections in immunocompromised patients, but infections in LT recipients are exceedingly rare (36,37).”
BackgroundNguyen, M. H., Wissel, M. C., Shields, R. K., Salomoni, M. A., Hao, B., Press, E. G., Shields, R. M., Cheng, S., Mitsani, D., Vadnerkar, A., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis200 · Cited by 290 · cited 1×
“The 19% (3/16) rate of candidemia among patients with intraabdominal candidiasis was also in agreement with earlier studies (34,35).”
ResultSelf-citationCryptococcus neoformans Infection in Patients With Cirrhosis, Including Liver Transplant Candidates
Singh, N., Husain, S., de Vera, M., Gayowski, T., & Cacciarelli, T. V. (2004) · Medicine · doi:10.1097/01.md.0000126760.45299.69 · Cited by 113
Jacobsen, I. D., Lüttich, A., Kurzai, O., Hube, B., & Brock, M. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku198 · Cited by 73
Cited by
Candida albicans—The Virulence Factors and Clinical Manifestations of Infection
Talapko, J., Juzbašić, M., Matijević, T., Pustijanac, E., Bekić, S., Kotris, I., & Škrlec, I. (2021) · Journal of Fungi · doi:10.3390/jof7020079 · Cited by 794
“Targeted antifungal prophylaxis is warranted in high-risk recipients of the liver, pancreas, small intestine, or hematopoietic stem cells [166].”
BackgroundHusain, S., & Camargo, J. F. (2019) · Clinical Transplantation · doi:10.1111/ctr.13544 · Cited by 302
Viehman, J. A., Clancy, C. J., Clarke, L., Shields, R. K., Silveira, F. P., Kwak, E. J., Vergidis, P., Hughes, C., Humar, A., & Nguyen, M. H. (2016) · Transplantation · doi:10.1097/tp.0000000000001356 · Cited by 90
Self-citationBadrane, H., Cheng, S., Dupont, C., Hao, B., Driscoll, E., Morder, K., Liu, G., Newbrough, A., Fleres, G., Kaul, D., et al. (2023) · doi:10.21203/rs.3.rs-2706400/v1 · Cited by 48
Self-citationKim, D.-S., Yoon, Y.-I., Kim, B. K., Choudhury, A., Kulkarni, A., Park, J. Y., Kim, J., Sinn, D. H., Joo, D. J., Choi, Y., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10629-3 · Cited by 47
Metadata
- Authors
- Eschenauer, G. A., Kwak, E. J., Humar, A., Potoski, B. A., Clarke, L. G., Shields, R. K., Abdel-Massih, R., Silveira, F. P., Verhidis, P., Clancy, C. J., & Nguyen, M. H.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 15
- Issue
- 1
- Pages
- 180-189
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W1758447972
- Cited by
- 85
- References
- 8
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted Versus Universal Antifungal Prophylaxis Among Liver Transplant Recipients. https://app.cochat.ai/papers/10.1111/ajt.12993
- The paper
- Eschenauer, G. A., Kwak, E. J., Humar, A., Potoski, B. A., Clarke, L. G., Shields, R. K., Abdel-Massih, R., Silveira, F. P., Verhidis, P., Clancy, C. J., & Nguyen, M. H. (2015). Targeted Versus Universal Antifungal Prophylaxis Among Liver Transplant Recipients. American Journal of Transplantation. https://doi.org/10.1111/ajt.12993
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.